In the news

The clinical trial found a correlation between survival and radiation absorbed by the tumor, giving Boston Scientific data to make the case for using the recently approved device.

The FDA has approved TheraSphere™ Yttrium-90 (Y-90) Glass Microspheres for the treatment of patients with hepatocellular carcinoma.

Boston Scientific aims to acquire Lumenis’ global surgical laser business, through a $1.07 billion deal that will incorporate its systems for ear, nose and throat procedures and its Moses laser treatment for breaking apart kidney stones.

Boston Scientific is making moves to strengthen its line of rhythm management diagnostics with the acquisition of privately held Preventice Solutions, Inc., a company that not only offers remote monitoring for cardiac issues, but also integrates deep learning algorithms and artificial intelligence to generate data used in diagnosis.

Boston Scientific’s Vercise Genus deep brain stimulation (DBS) system portfolio is approved for conditional use in a magnetic resonance imaging (MRI) environment. It features a family of Bluetooth-enabled, rechargeable and non-rechargeable implantable pulse generators capable of powering Cartesia directional leads to offer symptom relief for those suffering from Parkinson’s disease.